Related Experiment Videos
Thrombolysis and its sequelae. Calcium antagonists as potential adjunctive therapy
1Baylor College of Medicine, Methodist Hospital, Houston, Texas 77030.
Circulation
|December 1, 1989
Summary
Thrombolytic therapy for heart attacks improves outcomes but risks rethrombosis. Calcium blockers, like diltiazem, show promise as adjunctive therapy to prevent reinfarction and improve long-term benefits.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Thrombolytic therapy (streptokinase, rt-PA) limits infarct size and improves outcomes but has risks like rethrombosis.
- Experimental data suggests calcium blockers protect the heart during reperfusion.
- Clinical data on calcium blockers combined with thrombolysis is lacking.
Purpose of the Study:
- To evaluate the potential role of calcium blockers as adjunctive therapy following thrombolysis.
- To assess the impact of calcium blockers on reinfarction rates and long-term outcomes in patients with non-Q wave infarction.
Main Methods:
- Review of randomized, placebo-controlled trials on thrombolytic agents.
- Analysis of two randomized trials using diltiazem in patients with non-Q wave infarction.
- Consideration of experimental data on calcium blockers and reperfusion injury.
Main Results:
- Two trials involving diltiazem in non-Q wave infarction showed reduced early reinfarction by 50%.
- Long-term follow-up (1-4.5 years) demonstrated a 34-40% reduction in reinfarction and death.
- Non-Q wave infarction is associated with spontaneous reperfusion and a high reinfarction rate.
Conclusions:
- Thrombolysis, spontaneous or therapeutic, is linked to a high reinfarction incidence.
- Calcium blockers may be a crucial adjunctive therapy to prevent rethrombosis after thrombolysis.
- Further clinical evaluation of calcium blockers as adjunctive therapy post-thrombolysis is warranted.